Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2023

01-02-2023 | Ovarian Cancer | AdisInsight Report

Mirvetuximab Soravtansine: First Approval

Author: Young-A Heo

Published in: Drugs | Issue 3/2023

Login to get access

Abstract

Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere™) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. The ADC is being developed by ImmunoGen for the treatment of FRα expressing cancers. In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1–3 prior systemic treatment regimens. This article summarizes the milestones in the development of mirvetuximab soravtansine leading to this first approval.
Appendix
Available only for authorised users
Literature
1.
Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in Ovarian cancer models. Neoplasia. 2016;18(12):775–84.CrossRefPubMedPubMedCentral
2.
Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FR alpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR alpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402–7.CrossRefPubMedPubMedCentral
3.
Food & Drug Administration. FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer [media release]. 14 Nov 2022. https://​www.​fda.​gov/​
4.
5.
Yam C, Rauch GM, Rahman T, et al. A phase II study of mirvetuximab soravtansine in triple-negative breast cancer. Invest New Drugs. 2021;39(2):509–15.CrossRefPubMed
6.
National Comprehensive Cancer Network. NCCN receives $2-million funding commitment from ImmunoGen Inc. to study mirvetuximab soravtansine for folate receptor alpha-positive cancers [media release]. 18 May 2015. http://​www.​nccn.​org.
7.
National Comprehensive Cancer Network. NCCN awards research grants to eight investigators to support clinical and pre-clinical studies of mirvetuximab soravtansine in various cancers [media release]. 7 Jun 2016. http://​www.​nccn.​org.
8.
ImmunoGen, Merck. ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with Keytruda®(pembrolizumab) for the treatment of ovarian cancer [media release]. 4 Feb 2016. http://​www.​immunogen.​com.
9.
ImmunoGen, Huadong Medicine. ImmunoGen and Huadong Medicine announce strategic collaboration to develop and commercialize mirvetuximab soravtansine in Greater China [media release]. 20 Oct 2020. www.​immunogen.​com.
10.
Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015;14(7):1605–13.CrossRefPubMed
11.
Altwerger G, Bonazzoli E, Bellone S, et al. In vitro and In vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018;17(5):1003–11.CrossRefPubMedPubMedCentral
12.
Chelariu-Raicu A, Stur E, Ivan C, et al. Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer [abstract no 1237]. Cancer Res. 2020;80(16 Suppl):2.
13.
Moore KN, Lorusso D, Oaknin A, et al. Population pharmacokinetic analysis of mirvetuximab soravtansine in patients with folate receptor α–positive cancer [abstract no 605P]. Ann Oncol. 2022;33(Suppl 7):S822–3.CrossRef
14.
Matulonis U, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study [abstract no LBA4]. Gynecol Oncol. 2022;166(Suppl 1):S50.CrossRef
15.
Matulonis UA, Oaknin A, Pignata S, et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: characterization of antitumor activity in the SORAYA study [abstract no 5512]. J Clin Oncol. 2022;40(16 Suppl):1.
16.
Coleman RL, Lorusso D, Oaknin A, et al. Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the SORAYA study [abstract no. 376]. Int J Gynecol Cancer. 2022;32(Suppl 3).
17.
Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757–65.CrossRefPubMed
18.
Moore KN, Oza AM, Colombo N, et al. Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) [abstract no 532P]. Ann Oncol. 2022;33(Suppl 7):S790–1.CrossRef
19.
Moore K, Oza A, Colombo N, et al. FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) [abstract no 992O]. Ann Oncol 2019;30 (Suppl 5):v403.
20.
Oaknin A, Lorusso D, Oza A, et al. Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alphapositive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine [abstract no. 2022-RA-660-ESGO and poster presentation]. Int J Gynecol Cancer. 2022;32(Suppl 2):A2251–2.
21.
Matulonis UA, Moore KN, Lorusso D, et al. Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor [alpha] (FR[alpha])-positive cancer [abstract no 592P]. Ann Oncol. 2022;33(Suppl 7):S817.CrossRef
22.
O’Malley DM, Oaknin A, Matulonis UA, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis [abstract no 5504]. J Clin Oncol. 2021;39(15 Suppl):3.
23.
O’Malley DM, Richardson DL, Vergote IB, et al. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer [abstract no. 833P]. Ann Oncol. 2020;31(Suppl 4):S626–7.CrossRef
24.
O’Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379–85.CrossRefPubMed
25.
ImmunoGen. ImmunoGen announces positive findings from the FORWARD II study of mirvetuximab soravtansine combination regimens with Avastin® and carboplatin in ovarian cancer [media release]. 16 May 2018. http://​www.​immunogen.​com.
26.
Moore, KN, O'Malley DM, Vergote I, et al. Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis [abstract no 499]. Int J Gynecol Cancer. 2022;32(Suppl 3):A33–4.
27.
Matulonis U, Moore K, Martin L, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): initial results of an expansion cohort from FORWARD II, a phase Ib study [abstract no 949P]. Ann Oncol. 2018;29(Suppl 8):viii339.CrossRef
28.
O’Malley D, Oaknin A, Matulonis U, et al. Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab [abstract no 496]. Int J Gynecol Cancer. 2022;32(Suppl 3):16–7.
29.
Backes F, Wei L, Copeland L, et al. Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer [abstract no 120]. Gynecol Oncol. 2021;162(Suppl 1):S68–9.CrossRef
30.
Cristea MC, Ruel NH, Frankel PH, et al. A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (pts) with selected FR alpha-positive solid tumors: results in the ovarian cancer (EC) cohort [abstract no. 5542]. J Clin Oncol. 2021;39(15 Suppl).
31.
Moore KN, Borghaei H, O’Malley DM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080–7.CrossRefPubMed
32.
Moore KN, Martin LP, O’Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112–8.CrossRefPubMed
33.
ImmunoGen. ImmunoGen announces new clinical data with mirvetuximab soravtansine in ovarian cancer to be presented at 2017 ASCO annual meeting [media release]. 18 May 2017. http://​www.​immunogen.​com.
34.
Moore KN, Lorusso D, Oaknin A, et al. Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: phase 1 and 3 clinical trials [abstract no 5574]. J Clin Oncol. 2022;40(16 Suppl):1.
35.
Roche. Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for Elahere [media release]. 14 Nov 2022. http://​www.​roche.​com.
36.
Metadata
Title
Mirvetuximab Soravtansine: First Approval
Author
Young-A Heo
Publication date
01-02-2023
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2023
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-023-01834-3

Other articles of this Issue 3/2023

Drugs 3/2023 Go to the issue

AdisInsight Report

Adagrasib: First Approval

Therapy in Practice

Diagnosis and Treatment of AL Amyloidosis

Current Opinion

Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?

Original Research Article

Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study

Review Article

Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update